A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 7, 2008, Pages 3224-3230

  Noorwez, Syed M ^a   Ostrov, David A ^a   McDowell, J Hugh ^a   Krebs, Mark P ^a   Kaushal, Shalesh ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,.5 DIMETHYL 1H PYRAZOL 4 YL)ETHANONE; BETA IONONE; CHAPERONE; MUTANT PROTEIN; NSC 163936; NSC 170691; NSC 227405; NSC 45012; NSC 47520; OPSIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 1 (3,5 DIMETHYL 1H PYRAZOL 4 YL)ETHANONE; 1-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)ETHANONE; BETA-IONONE; HISTIDINE; NORISOPRENOID; PROLINE; PYRAZOLE DERIVATIVE; RHODOPSIN;

ARTICLE; CELL ASSAY; COMPUTER MODEL; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; INCUBATION TIME; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; WILD TYPE; ANIMAL; CATTLE; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETICS; MOLECULAR WEIGHT; MUTATION;

ANIMALS; CATTLE; CELL LINE; HISTIDINE; MOLECULAR CHAPERONES; MOLECULAR WEIGHT; MUTATION; NORISOPRENOIDS; PROLINE; PROTEIN FOLDING; PYRAZOLES; RHODOPSIN;

EID: 48249108690     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1539     Document Type: Article

References (33)

1. Arakawa T, Ejima D, Kita Y, Tsumoto K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta. 2006;1764:1677-1687.
2. Tao YX. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol Ther. 2006;111:949-973.
3. Bernier V, Lagace M, Bichet DG, Bouvier M. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab. 2004;15:222-228.
4. Krebs MP, Noorwez SM, Malhotra R, Kaushal S. Quality control of integral membrane proteins. Trends Biochem Sci. 2004;29:648-655.
5. Selkoe DJ. Folding proteins in fatal ways. Nature. 2003;426:900-904.
6. Bonapace G, Waheed A, Shah GN, Sly WS. Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad Sci USA. 2004;101:12300-12305.
7. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic. 2004;5:821-837.
8. Schulein R. The early stages of the intracellular transport of membrane proteins: clinical and pharmacological implications. Rev Physiol Biochem Pharmacol. 2004;151:45-91.
9. Li T, Sandberg MA, Pawlyk BS, et al. Effect of vitamin A supplementation on rhodopsin mutants threonine-17→methionine and proline-347→serine in transgenic mice and in cell cultures. Proc Natl Acad Sci U S A. 1998;95:11933-11938.
10. Sawkar AR, D'Haeze W, Kelly JW. Therapeutic strategies to ameliorate lysosomal storage disorders: a focus on Gaucher disease. Cell Mol Life Sci. 2006;63:1179-1192.
11. Kennan A, Aherne A, Humphries P. Light in retinitis pigmentosa. Trends Genet. 2005;21:103-110.
12. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795-1809.
13. Kaushal S, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry. 1994;33:6121-6128.
14. Saliba RS, Munro PM, Luthert PJ, Cheetham ME. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J Cell Sci. 2002;115:2907-2918.
15. Illing ME, Rajan RS, Bence NF, Kopito RR. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J Biol Chem. 2002;277:34150-34160.
16. Noorwez SM, Kuksa V, Imanishi Y, et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem. 2003;278:14442-14450.
17. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP, Kaushal S. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem. 2004;279:16278-16284.
18. Matsumoto H, Yoshizawa T. Existence of a beta-ionone ring-binding site in the rhodopsin molecule. Nature. 1975;258:523-526.
19. Daemen FJ. The chromophore binding space of opsin. Nature. 1978;276:847-848.
20. Crouch RK, Veronee CD, Lacy ME. Inhibition of rhodopsin regeneration by cyclohexyl derivatives. Vision Res. 1982;22:1451-1456.
21. Towner P, Gaertner W, Walckhoff B, Oesterhelt D, Hopf H. Regeneration of rhodopsin and bacteriorhodopsin; the role of retinal analogues as inhibitors. Eur J Biochem. 1981;117:353-359.
22. Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR, Neubig RR. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol. 2007;71:169-175.
23. Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol Pharmacol. 2007;71:1061-1074.
24. Shoichet BK, McGovern SL, Wei B, Irwin JJ. Lead discovery using molecular docking. Curr Opin Chem Biol. 2002;6:439-446.
25. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 2001;15:411-428.
26. Evans SV. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. J Mol Graph. 1993;11:134-138.
27. Kefalov VJ, Carter CM, Crouch RK. Occupancy of the chromophore binding site of opsin activates visual transduction in rod photoreceptors. J Gen Physiol. 1999;113:491-503.
28. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289:739-745.
29. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
30. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG, Conn PM. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther. 2003;305:608-614.
31. Ficker E, Obejero-Paz CA, Zhao S, Brown AM. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem. 2002;277:4989-4998.
32. Edwards BS, Bologa C, Young SM, et al. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol. 2005;68:1301-1310.
33. Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions: docking and scoring: successes and gaps. J Med Chem. 2006;49:5851-5855.